← All trials
NCT04539951
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2020
- Primary completion
- Aug 31, 2023
- Completion date
- Dec 31, 2024
- First posted
- Sep 7, 2020
- Last posted
- Dec 22, 2020
- Enrollment
- 1600
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Jiao Tong UniversityLead sponsor
- Nanchang UniversityCollaborator
- Jinan UniversityCollaborator
- Kunming Medical UniversityCollaborator
- Guizhou Medical UniversityCollaborator
- Ningxia Medical UniversityCollaborator
- Sichuan UniversityCollaborator
- Jiao Tong UniversityReponsible party - principal investigator
- Jiao Tong UniversityOverall official - principal investigator
- Henan Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Hangzhou Seventh People's HospitalCollaborator
- Suzhou Psychiatric HospitalCollaborator
- the First Specialized Subject Hospital of HarbinCollaborator
- Wuhan Mental Health CentreCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.